Strong discontent with the new rebate measures expressed by Greek pharma

The Greek pharma industry, via its trade group the SfEE, has expressed its strong discontent and deep concern about the new across-the-board measures announced by the Ministry of Health (in particular the unified volume rebate, which puts an additional burden of 25% on new on-patent medicines).

These measures are not structural reforms; they are harsh tax-collecting measures, which do not deliver on the memorandum of understanding (MoU) commitment to reduce the claw-back by 30%. In fact, these measures restrict, or even prohibit, the entry of new innovative medicines, with direct and adverse effects on Greek patients, said the SfEE. In addition, they deal a blow to healthy entrepreneurship, without ensuring solid fiscal gains or, most importantly, better healthcare.

Finally, they exhaust the viability of pharmaceutical companies, threatening the 86,000 jobs directly and indirectly supported by the Industry, and create conditions of disinvestment.